Practical implications for the administration of 13-cis retinoic acid in pediatric oncology

Riferimento: 
Int J Clin Pharm. 2011 Aug;33(4):597-8.
Autori: 
Bauters TG, Laureys G, Van de Velde V, Benoit Y, Robays H. tiene.bauters@uzgent.be
Fonte: 
Int J Clin Pharm. 2011 Aug;33(4):597-8.
Anno: 
2011
Azione: 
La presente relazione descrive alcune raccomandazioni pratiche per la somministrazione di acido 13-cRA nei bambini trattati per neuroblastoma ad alto rischio.
Target: 
13-cRA/neuroblastoma.

ABSTRACT
Children with high-risk neuroblastoma are treated with polychemotherapy, surgery, radiotherapy and even autologous stem-cell transplantation. On top of this complex treatment, most children also receive 13-cis retinoic acid as differentiation agent. As no suitable pharmaceutical formulation is available so far, there are often problems with the administration of the product in children. The present report describes some practical recommendations for the administration of isotretinoin in children treated for high-risk neuroblastoma.

Sostanze: